N/A N=8 Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
Multiple Myeloma
Primary: Number of Participants With Immune Response — 5; 5; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=88 Anti-Helicobacter Pylori Antibodies (IgG) in Serum of Women With Unexplained Infertility
Infertility, Female
Primary: Quantitative Helicobacter Pylori IgG Assay in Serum — 70; 70 arbitrary unit per millilitre — p=<0.001
N/A N=60 The Association Between Endometriosis, Obesity and nesfatin1
Endometriosis
Primary: Serum Nesfatin 1 — 190; 510 picogram/millilitre — p=0.05
Phase 3 N=103 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
Hepatitis C Virus Infection
Primary: Percentage of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Actual End of Treatment (EOT) — 83.5 Percentage of Participants
Phase 4 N=65 Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
High Triglycerides · Hypercholesterolemia · Schizophrenia
Primary: Change in Triglycerides From Baseline to 16 Weeks — -54.13 mg/dL
N/A N=209 An Observational Study in Clinical Practice Management of Patients With Biological Drugs in Monotherapy
Rheumatoid Arthritis
Primary: Number of Participants With Level of Education Completed — 01; 15; 86; 59 Participants
N/A N=70 The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery
Pain
Primary: Qor-40 at 24 Hours Postoperative — 179; 182 units on a scale 40 low-200 high — p=.82
N/A N=191 Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
Atrial Fibrillation · Hemorrhage
Primary: Proportion of Subjects With Index Event Safety Outcomes (Resolved / Recovery Ongoing / Deceased) at the Time of Their Hospital Discharge / Release. — 86.4; 7.3; 6.3…
N/A N=20 Positron Emission Mammography (PEM) Biopsy Accessory for the Diagnosis of Breast Cancer
Breast Cancer
Primary: Feasibility That Breast Biopsy Can be Performed Using PEM and Stereo Navigator Software After Diagnostic PEM on the Same Day. — 22; 21; 6; 26 Breast Lesions
Phase 2 N=11 Autologous Dendritic Cell Vaccine in HIV1 Infection
HIV Infections
Primary: Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. — 2 participants with Grade 3 events related
Early Phase 1 N=25 Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
Melanoma
Primary: Number of Participants With Treatment-related Adverse Events as a Measure of Safety and Tolerability — 1; 0; 4; 2 participants
N/A N=49 Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study
Type 1 Diabetes
Primary: Time in Target Blood Glucose Range — 15.28; 15.31; 14.56; 14.14 hours per day — p=0.0926
Phase 2 N=57 Dutch Acute HCV in HIV Study (DAHHS)
Hepatitis C · Human Immunodeficiency Virus
Primary: Sustained Viral Response(SVR) 12 Weeks of Follow up After the End of All Therapy for the Rapid Viral Response at Week 4(RVR4) Population. — 41 participants
N/A N=59 Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment
Pathological Gambling
Primary: Perceived Stress Scale — 15.2; 14.5 units on a scale
Phase 2 N=17 A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression Free Survival — 23.3; 24.4 Week — p=0.3644